The combination of a lung cancer vaccine plus chemotherapy has been proven to help more patients live without their cancer progressing than chemotherapy alone, a study has revealed.
The research, led by the University of Strasbourg, involved 148 patients with non-small-cell lung cancer, the most common form of the disease.
Results published in The Lancet Oncology showed that 43% of the 74 patients treated with Trasgene’s TG4010 vaccine in combination with chemotherapy survived for six months without the disease progressing, while the progression-free survival rate in the 74 patients treated with chemotherapy alone was 35%.
TG4010 is designed to trigger the immune system and target the MUC1 protein, which is overproduced by tumour cells in advanced lung cancer.
France-based gene therapy group Transgene funded the phase IIb trial.
